2 L’association entre critère intermédiaire et critère clinique ne fait pas un surrogate
5 Situation actuelle, méta-épidémiologie
Références
[1] Shyr Y, Shyr D. What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials? JAMA Oncol 2020 10.1001/jamaoncol.2020.1847
[2] Lee H, Herbert RD, Lamb SE, et al. Investigating causal mechanisms in randomised controlled trials. Trials 2019;20:524 10.1186/s13063-019-3593-z [31443729]
[3] Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14 10.1016/0002-9343(77)90874-9 [193398]
[4] Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15 10.1161/01.cir.79.1.8 [2642759]
[5] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109–22 10.1056/NEJMoa0706628 [17984165]
[6] Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–09 10.1056/NEJM199003223221203 [2407957]
[7] Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. Eur. Heart J. 2015;36:2212–18 10.1093/eurheartj/ehv164 [25975658]
[8] Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006;5:173–86 10.1002/pst.207 [17080751]
[9] Buyse M, Molenberghs G, Paoletti X, et al. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials: Statistical evaluation of surrogate endpoints. Biometrical Journal 2016;58:104–32 10.1002/bimj.201400049
[10] Ciani O, Buyse M, Drummond M, et al. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nature Reviews Drug Discovery 2016;15:516 10.1038/nrd.2016.81
[11] Bujkiewicz S, Thompson JR, Spata E, et al. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints. Stat Methods Med Res 2017;26:2287–318 10.1177/0962280215597260
[12] Ciani O, Davis S, Tappenden P, et al. VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care 2014;30:312–24 10.1017/S0266462314000300
[13] IQWiG. Validity of surrogate endpoints in oncology. Cologne 2011.
[14] Norsworthy KJ, Gao X, Ko C-W, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. JCO 2022;40:847–54 10.1200/JCO.21.01548 [34890212]
[15] Lassere MN, Johnson KR, Schiff M, et al. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). BMC Med Res Methodol 2012;12:27 10.1186/1471-2288-12-27 [22409774]
[16] Ciani O, Buyse M, Drummond M, et al. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value in Health 2017;20:487–95 10.1016/j.jval.2016.10.011
[17] Paoletti X, Lewsley LA, Daniele G, et al. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e1918939 10.1001/jamanetworkopen.2019.18939 [31922558]
[18] Xie W, Regan MM, Buyse M, et al. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology 2017:JCO.2017.73.9987 10.1200/JCO.2017.73.9987
[19] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet 2014;384:164–72 10.1016/S0140-6736(13)62422-8 [24529560]
[20] Head ML, Holman L, Lanfear R, et al. The extent and consequences of p-hacking in science. PLoS Biology 2015;13:e1002106 10.1371/journal.pbio.1002106 [25768323]
[21] Data dredging - Wikipedia 2021. Available at: https://en.wikipedia.org/wiki/Data_dredging Accessed August 30, 2021.
[22] Kerr NL. HARKing: hypothesizing after the results are known. Pers Soc Psychol Rev 1998;2:196–217 10.1207/s15327957pspr0203_4 [15647155]
[23] Siontis KC, Hernandez-Boussard T, Ioannidis JPA. Overlapping meta-analyses on the same topic: survey of published studies. BMJ 2013;347:f4501 10.1136/bmj.f4501 [23873947]
[24] Ioannidis JPA. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. The Milbank Quarterly 2016;94:485–514 10.1111/1468-0009.12210 [27620683]
[25] van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589–624 10.1002/sim.1040 [11836738]
[26] Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–73 10.1002/sim.1187 [12111920]
[27] Papanikos T, Thompson JR, Abrams KR, et al. A novel approach to bivariate meta-analysis of binary outcomes and its application in the context of surrogate endpoints 2020.
[28] Branchoux S, Sofeu CL, Gaudin A-F, et al. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open 2021;7:100340 10.1016/j.esmoop.2021.100340 [34929616]
[29] Baker SG. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials. Stat Med 2018;37:507–18 10.1002/sim.7561 [29164641]
[30] Sofeu CL, Emura T, Rondeau V. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. Stat Med 2019;38:2928–42 10.1002/sim.8162 [30997685]
[31] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 2005;366:1267–78 10.1016/S0140-6736(05)67394-1 [16214597]
[32] Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–12 10.1056/NEJMoa1300955 [25014686]
[33] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713–22 10.1056/NEJMoa1615664 [28304224]
[34] Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 2009;373:1175–82 10.1016/S0140-6736(09)60447-5 [19329177]
[35] Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005;2013:CD002230 10.1002/14651858.CD002230.pub2 [15674893]
[36] Naci H, Davis C. Inappropriate use of progression-free survival in cancer drug approvals. BMJ-BRITISH MEDICAL JOURNAL 2020;368:m770 10.1136/bmj.m770 [32156802]
[37] Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 2017;15:134 10.1186/s12916-017-0902-9 [28728605]
[38] Hilal T, Gonzalez-Velez M, Prasad V. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2020;180:1108–15 10.1001/jamainternmed.2020.2250 [32539071]
[39] Chen EY, Joshi SK, Tran A, et al. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Internal Medicine 2019;179:642–47 10.1001/jamainternmed.2018.8351 [30933235]
[40] Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine 2019;179:906–13 10.1001/jamainternmed.2019.0462 [31135808]
[41] Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368–77 10.1001/jama.2013.282034 [24449315]
[42] Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA 2017;318:626–36 10.1001/jama.2017.9415 [28810023]
[43] Pease AM, Krumholz HM, Downing NS, et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ-BRITISH MEDICAL JOURNAL 2017;357:j1680 10.1136/bmj.j1680 [28468750]
[44] Prasad V, Kim C, Burotto M, et al. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Internal Medicine 2015;175:1389–98 10.1001/jamainternmed.2015.2829 [26098871]
[45] Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218–24 10.1200/JCO.2007.11.8836 [18024867]
[46] Ciani O, Buyse M, Garside R, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol 2015;68:833–42 10.1016/j.jclinepi.2015.02.016 [25863582]
[47] Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Internal Medicine 2015;175:1992–94 10.1001/jamainternmed.2015.5868 [26502403]
[48] Chen EY, Haslam A, Prasad V. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Internal Medicine 2020;180:912–14 10.1001/jamainternmed.2020.1097 [32338703]
[49] Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Internal Medicine 2019;179:915–21 10.1001/jamainternmed.2019.0583 [31135822]
[50] Wallach JD, Ciani O, Pease AM, et al. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. BMC Med 2018;16:45 10.1186/s12916-018-1023-9 [29562926]
